Dual TTK/PLK1 inhibition has potent anticancer activity in TNBC as monotherapy and in combination by Elisa Zanini, Nicole Forster-Gross, Felix Bachmann, Adrian Brüngger, Paul McSheehy, Karine Litherland, Karin Burger, Anna C. Groner, Mila Roceri, Luc Bury, Martin Stieger, Nicole Willemsen-Seegers, Jos de Man, Diep Vu-Pham, Helma W. E. van Riel, Guido J. R. Zaman, Rogier C. Buijsman, Laurenz Kellenberger, Heidi A. Lane

Get full text

Selective CK1α degraders exert antiproliferative activity against a broad range of human cancer cell lines by Gisele Nishiguchi, Lauren G. Mascibroda, Sarah M. Young, Elizabeth A. Caine, Sherif Abdelhamed, Jeffrey J. Kooijman, Darcie J. Miller, Sourav Das, Kevin McGowan, Anand Mayasundari, Zhe Shi, Juan M. Barajas, Ryan Hiltenbrand, Anup Aggarwal, Yunchao Chang, Vibhor Mishra, Shilpa Narina, Melvin Thomas, Allister J. Loughran, Ravi Kalathur, Kaiwen Yu, Suiping Zhou, Xusheng Wang, Anthony A. High, Junmin Peng, Shondra M. Pruett-Miller, Danette L. Daniels, Marjeta Urh, Anang A. Shelat, Charles G. Mullighan, Kristin M. Riching, Guido J. R. Zaman, Marcus Fischer, Jeffery M. Klco, Zoran Rankovic

Get full text